Monthly run archive / October 2026
Modern Formula Full Universe Top 40
October 4, 2026 research cycle. Model entry: October 5, 2026 close.
This October research version is being archived after the model entry date. Results are a retrospective model comparison, not evidence of a portfolio published before entry. The run date labels the research cycle; the actual public timestamp is the hosting deployment record.
First worksheet; original rank order.
Model performance
Portfolio and benchmark.
Portfolio closes: October 5, 2026. Benchmark close: October 5, 2026.
- Weighted portfolio return
- 0.00%
- VTI return
- 0.00%
- Difference vs. VTI
- +0.00 pp
Price returns from the entry close, before dividends, fees, and taxes. Splits and other corporate actions require review. Each portfolio is tracked separately; overlapping holdings are not combined into a single track record.
Top-40 model portfolio
Holdings and entry prices.
Per our target weighting, this run uses the top 40 ranked names and applies rank-weighted model allocations. Ranks 1-12, their prices and individual returns, and exact allocations are reserved for members.
Membership access Download public entry snapshot CSV
40 of 40 entry prices recorded. Latest portfolio closes: October 5, 2026.
| Rank | Ticker | Tier | Allocation | Entry date | Entry price | Latest close | Price return |
|---|---|---|---|---|---|---|---|
| 1 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 2 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 3 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 4 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 5 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 6 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 7 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 8 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 9 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 10 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 11 | Subscriber Only | Core | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 12 | Subscriber Only | Core | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 13 | OSPN | Core | Member Only | October 5, 2026 close | $18.42 | $18.42 | 0.00% |
| 14 | PBI | Core | Member Only | October 5, 2026 close | $16.81 | $16.81 | 0.00% |
| 15 | PFE | Core | Member Only | October 5, 2026 close | $27.41 | $27.41 | 0.00% |
| 16 | ADEA | Core | Member Only | October 5, 2026 close | $26.07 | $26.07 | 0.00% |
| 17 | CHCI | Core | Member Only | October 5, 2026 close | $19.17 | $19.17 | 0.00% |
| 18 | THC | Core | Member Only | October 5, 2026 close | $259.47 | $259.47 | 0.00% |
| 19 | BBY | Core | Member Only | October 5, 2026 close | $87.39 | $87.39 | 0.00% |
| 20 | BMY | Core | Member Only | October 5, 2026 close | $58.81 | $58.81 | 0.00% |
| 21 | DLO | Standard | Member Only | October 5, 2026 close | $14.52 | $14.52 | 0.00% |
| 22 | IBEX | Standard | Member Only | October 5, 2026 close | $43.33 | $43.33 | 0.00% |
| 23 | INCY | Standard | Member Only | October 5, 2026 close | $114.13 | $114.13 | 0.00% |
| 24 | LAUR | Standard | Member Only | October 5, 2026 close | $38.51 | $38.51 | 0.00% |
| 25 | SJM | Standard | Member Only | October 5, 2026 close | $116.23 | $116.23 | 0.00% |
| 26 | WEX | Standard | Member Only | October 5, 2026 close | $172.48 | $172.48 | 0.00% |
| 27 | ZD | Standard | Member Only | October 5, 2026 close | $55.98 | $55.98 | 0.00% |
| 28 | MLI | Standard | Member Only | October 5, 2026 close | $62.97 | $62.97 | 0.00% |
| 29 | ADUS | Standard | Member Only | October 5, 2026 close | $112.98 | $112.98 | 0.00% |
| 30 | AUPH | Standard | Member Only | October 5, 2026 close | $15.72 | $15.72 | 0.00% |
| 31 | EAT | Starter | Member Only | October 5, 2026 close | $194.16 | $194.16 | 0.00% |
| 32 | GFF | Starter | Member Only | October 5, 2026 close | $94.09 | $94.09 | 0.00% |
| 33 | DSP | Starter | Member Only | October 5, 2026 close | $12.14 | $12.14 | 0.00% |
| 34 | SIG | Starter | Member Only | October 5, 2026 close | $100.89 | $100.89 | 0.00% |
| 35 | BLBD | Starter | Member Only | October 5, 2026 close | $57.03 | $57.03 | 0.00% |
| 36 | CCSI | Starter | Member Only | October 5, 2026 close | $36.38 | $36.38 | 0.00% |
| 37 | CVS | Starter | Member Only | October 5, 2026 close | $87.01 | $87.01 | 0.00% |
| 38 | CRCT | Starter | Member Only | October 5, 2026 close | $6.47 | $6.47 | 0.00% |
| 39 | RCMT | Starter | Member Only | October 5, 2026 close | $41.59 | $41.59 | 0.00% |
| 40 | WLY | Starter | Member Only | October 5, 2026 close | $48.54 | $48.54 | 0.00% |
Opportunity notes
Why the top 15 ranked here.
The score measures fit with the opportunity framework, not a forecast of future returns. Commentary summarizes the supplied October research version. Notes for ranks 1-12 are reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
OSPN
OneSpan's recurring security software, growing annual recurring revenue, and financial resources support the opportunity. Higher guidance and the Build38 acquisition add potential, but operating income needs to keep pace with adjusted earnings. Legacy hardware decline, acquisition integration, and cash costs temper the apparent discount.
PBI
Pitney Bowes offers a turnaround case grounded in improving operating profit, cash generation, and debt reduction. The strategic review may create additional options, but the valuation does not assume a sale or treat the stock as merger arbitrage. Secular mail decline and remaining leverage still constrain long-term earnings value.
PFE
Pfizer's established pharmaceutical franchises and non-COVID growth support a discounted operating value case. Restructuring may help, but the thesis does not depend on a return to pandemic windfalls. Patent expiries, acquisition debt, and the ongoing cost of replacing the pipeline remain material risks.
Show ranked research
| Rank | Ticker | Score | Band | Opportunity and risk |
|---|---|---|---|---|
| 1 | Subscriber Only | 83.5 | Strong MF fit | Detailed thesis reserved for members. |
| 2 | Subscriber Only | 75 | Good candidate with hair | Detailed thesis reserved for members. |
| 3 | Subscriber Only | 74.5 | Good candidate with hair | Detailed thesis reserved for members. |
| 4 | Subscriber Only | 73 | Good candidate with hair | Detailed thesis reserved for members. |
| 5 | Subscriber Only | 73 | Good candidate with hair | Detailed thesis reserved for members. |
| 6 | Subscriber Only | 72.5 | Good candidate with hair | Detailed thesis reserved for members. |
| 7 | Subscriber Only | 70 | Good candidate with hair | Detailed thesis reserved for members. |
| 8 | Subscriber Only | 69.5 | Interesting but messy | Detailed thesis reserved for members. |
| 9 | Subscriber Only | 69 | Interesting but messy | Detailed thesis reserved for members. |
| 10 | Subscriber Only | 69 | Interesting but messy | Detailed thesis reserved for members. |
| 11 | Subscriber Only | 68.5 | Interesting but messy | Detailed thesis reserved for members. |
| 12 | Subscriber Only | 68.5 | Interesting but messy | Detailed thesis reserved for members. |
| 13 | OSPN | 67.5 | Interesting but messy | OneSpan's recurring security software, growing annual recurring revenue, and financial resources support the opportunity. Higher guidance and the Build38 acquisition add potential, but operating income needs to keep pace with adjusted earnings. Legacy hardware decline, acquisition integration, and cash costs temper the apparent discount. |
| 14 | PBI | 66 | Interesting but messy | Pitney Bowes offers a turnaround case grounded in improving operating profit, cash generation, and debt reduction. The strategic review may create additional options, but the valuation does not assume a sale or treat the stock as merger arbitrage. Secular mail decline and remaining leverage still constrain long-term earnings value. |
| 15 | PFE | 66 | Interesting but messy | Pfizer's established pharmaceutical franchises and non-COVID growth support a discounted operating value case. Restructuring may help, but the thesis does not depend on a return to pandemic windfalls. Patent expiries, acquisition debt, and the ongoing cost of replacing the pipeline remain material risks. |
| 16 | ADEA | 65.5 | Interesting but messy | Adeia's patent licenses produce high-margin cash flow with limited physical capital needs, supported by renewals and semiconductor adoption. Contract timing, litigation costs, debt, and recurring operating expenses limit how much of adjusted earnings can be treated as dependable owner cash. |
| 17 | CHCI | 65.5 | Interesting but messy | Comstock's property-management and development fees support a profitable, capital-light business with cash and no funded debt in the supplied research. Related-party concentration and project timing constrain reliability, while investment gains and tax benefits should be separated from recurring operating earnings. |
| 18 | THC | 65.5 | Interesting but messy | Tenet's ambulatory-care operations, stronger cash flow, and repurchases support a continuing operating recovery. Leverage, reimbursement, and minority ownership in surgery centers mean consolidated earnings must be adjusted to determine the cash attributable to common shareholders. |
| 19 | BBY | 65 | Interesting but messy | Best Buy retains a profitable retail-and-services franchise with capital returns and recovery potential. Electronics replacement cycles, competition, and promotions limit normalized margins, and temporary tariff refunds should not be counted as recurring earnings. |
| 20 | BMY | 65 | Interesting but messy | Bristol Myers Squibb's growing commercial portfolio and higher guidance support substantial ongoing cash generation. Legacy patent erosion, acquisition spending, and necessary pipeline investment explain much of the discount and must remain in the valuation. |
| 21 | DLO | 65 | Interesting but messy | dLocal's expanding payments platform and strong balance sheet support its operating value. Falling gross profit relative to payment volume and rising costs make rapid volume growth an incomplete measure of shareholder earnings, with emerging-market exposure adding risk. |
| 22 | IBEX | 65 | Interesting but messy | IBEX combines revenue and earnings growth with cash generation and capital returns. Customer concentration, wage costs, and the potential for AI to replace outsourced service work limit the duration and valuation assigned to current earnings. |
| 23 | INCY | 65 | Interesting but messy | Incyte's Jakafi and Opzelura franchises support recurring commercial cash flow. A noncash reimbursement adjustment and acquired research charges complicate reported results, while patent concentration and pipeline spending remain the main valuation constraints. |
| 24 | LAUR | 65 | Interesting but messy | Laureate's established campuses and recurring enrollment in Mexico and Peru support cash earnings and capital returns. Currency exposure, tuition affordability, and education-sector regulation constrain the durability premium warranted by current growth. |
| 25 | SJM | 65 | Interesting but messy | Smucker's established food and beverage brands support recurring demand and a potential earnings recovery. Hostess integration, debt, commodity costs, and mature categories remain constraints, and tariff refunds should be excluded from normalized earnings. |
| 26 | WEX | 65 | Interesting but messy | WEX's fleet, travel, and benefits payments combine repeat business with operating leverage and repurchases. Fuel-price sensitivity, credit exposure, and financing liabilities require a more careful valuation than a simple comparison with debt-free software businesses. |
| 27 | ZD | 65 | Interesting but messy | Ziff Davis's completed Connectivity sale strengthened financial flexibility and supported share repurchases. Value should combine continuing earnings with post-transaction cash, without counting the disposed business twice, while AI and search disruption remain risks for the remaining portfolio. |
| 28 | MLI | 64.5 | Interesting but messy | Mueller Industries combines established manufacturing positions with cash resources and strong returns on capital. Copper pricing, construction demand, and acquisition contributions require normalized earnings rather than a valuation based on unusually favorable commodity margins. |
| 29 | ADUS | 64 | Interesting but messy | Addus HomeCare's scale, recurring care demand, and operating growth support its acquisition-led model. Medicaid reimbursement, labor availability, and integration execution limit the value gap at the current price. |
| 30 | AUPH | 64 | Interesting but messy | Aurinia's commercial LUPKYNIS franchise produces profits and cash flow, supported by a strong balance sheet and repurchases. Single-product dependence, patent duration, and continued growth spending constrain the multiple appropriate for those earnings. |
| 31 | EAT | 64 | Interesting but messy | Brinker's Chili's recovery and substantial repurchases reflect genuine operating improvement. The valuation offers less protection than at the trough, so traffic, food and labor costs, leases, and fiscal-year comparability need to be reflected in sustainable earnings. |
| 32 | GFF | 64 | Interesting but messy | Griffon's simplified portfolio, door-business cash flow, and repurchases support its value case. Housing demand and remaining debt are material risks, and disposed businesses' earnings should not be combined with the continuing company's capital structure. |
| 33 | DSP | 63.5 | Interesting but messy | Viant's connected-TV growth, measurement capabilities, and balance sheet support operating potential. Stock compensation and a high reported operating-earnings multiple weaken the apparent adjusted-earnings bargain despite strong revenue growth. |
| 34 | SIG | 63.5 | Interesting but messy | Signet Jewelers combines established jewelry brands, positive comparable sales, cash, and an accelerated repurchase program. Tariff refunds should be removed from normalized margins, while discretionary demand, lab-grown diamond pricing, inventory, and leases constrain the discount. |
| 35 | BLBD | 63 | Interesting but messy | Blue Bird benefits from school-bus replacement demand and higher guidance. Acquisition contributions and accounting gains complicate reported growth, so the valuation should use recurring combined-company earnings while allowing for weaker legacy bookings and subsidy exposure. |
| 36 | CCSI | 63 | Interesting but messy | Consensus Cloud's digital-fax and healthcare workflows generate recurring cash, with repurchases supporting per-share value. Legacy consumer decline, debt, and the durability of healthcare growth remain the principal limits on its operating valuation. |
| 37 | CVS | 63 | Interesting but messy | CVS's integrated pharmacy and insurance operations offer recovery potential supported by improved guidance and operating cash flow. Medical-cost trends, regulation, and leverage remain the main risks, while subsidiary restructuring should be distinguished from the parent's continuing business. |
| 38 | CRCT | 62.5 | Interesting but messy | Cricut's subscriptions, cash resources, and capital returns provide value support as hardware sales decline. Unusual items in operating profit and weaker product demand mean reported margin expansion should not be extrapolated as recurring growth. |
| 39 | RCMT | 62.5 | Interesting but messy | RCM Technologies combines engineering and healthcare staffing earnings with revenue growth at a reasonable valuation. Slower gross-profit growth, receivables, debt, and disclosed internal-control weaknesses warrant scrutiny before treating reported growth as durable value creation. |
| 40 | WLY | 62.5 | Interesting but messy | Wiley's research publishing supports recurring demand and cash generation, with restructuring providing potential value. Legacy pressure and weaker adjusted operating profit constrain the case, and one-time AI licensing agreements should not be valued as recurring subscriptions. |
Benchmarks
Comparison baseline.
| Benchmark | Entry date | Entry price | Status |
|---|---|---|---|
| VTI | October 5, 2026 close | $380.60 | Started |
| Magic Formula Top 50 over $50M | Pending constituent list and entry prices | ||
Publication ledger
Research version and record.
- Research cycle
- October 4, 2026
- Entry date
- October 5, 2026 close.
- Latest dated source information
- September 21, 2026
- Publication timing
- Prepared after entry. See the hosting deployment record for the actual public timestamp.
- Source workbook
- Consolidated_Oct-2026_FULL_UNIVERSE.xlsx
- Source worksheet
- Consolidated
- Ranking CSV SHA-256
60f95baa09a72e1c9b58b7692348081882c36f4a81172e2bd0322487e23d9dcf- Portfolio CSV SHA-256
4905fad044f8ebbed0d881016d5889f3a8690e1ecb531b13329daaf3b647916d- Manifest
- View publication manifest
Preserve the original publication and record any corrections with a new date. Portfolio closes can be updated separately from the archived research.